Association between immunosuppressants and poor antibody responses to SARS-CoV-2 vaccines in patients with autoimmune liver diseases.
Association between immunosuppressants and poor antibody responses to SARS-CoV-2 vaccines in patients with autoimmune liver diseases.
复制标题
自身免疫性肝病患者免疫抑制剂与 SARS-CoV-2 疫苗抗体反应不良之间的关联
DOI：
10.3389/fimmu.2022.988004
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
Ren, Hong
中科院分区：
文献类型：
--
作者：
Li, Hu;Wang, Yuting;Ao, Ling;Ke, Mingxia;Chen, Zhiwei;Chen, Min;Peng, Mingli;Ling, Ning;Hu, Peng;Cai, Dachuan;Zhang, Dazhi;Ren, Hong
关键词：
自身免疫性肝病 (AILD) 患者在灭活 SARS-CoV-2 疫苗接种后的抗体和 B 细胞反应尚未得到充分记录。因此，我们于2021年7月1日至2021年9月30日在重庆医科大学第二附属医院开展了一项前瞻性观察研究，其中包括AILD患者和健康参与者作为对照。记录并分级 COVID-19 疫苗接种后的所有不良事件 (AE)。在全程疫苗接种（BBIBP-CorV 或 CoronaVac）后，测试了针对 SARS-CoV-2 刺突蛋白受体结合域 (RBD) 的免疫球蛋白 (Ig)-G 抗体（抗 RBD-IgG）和中和抗体 (NAb)。此外，通过流式细胞术检测了 SARS-CoV-2 特异性 B 细胞。总共包括 76 名 AILD 患者和 136 名健康对照 (HC)。所有 AE 均为轻度且具有自限性，AILD 和 HC 之间的发生率相似。 AILD 中抗 RBD-IgG 和 NAb 的血清阳性率分别为 97.4%（HC 中为 100%，p = 0.13）和 63.2%（HC 中为 84.6%，p < 0.001）。 AILD 患者的抗 RBD-IgG 和 NAb 滴度显着低于 HC。调整混杂因素后，免疫抑制治疗是低水平抗 RBD-IgG 的独立危险因素（调整后比值比 [aOR]：4.7；95% 置信区间 [CI]，1.5-15.2；p = 0.01），并降低 NAbs 血清阳性概率（aOR，3.0；95% CI，1.0-8.9；p = 0.04）在 AILD 患者中。然而，无论使用何种免疫抑制剂，AILD 组和 HC 组之间的 SARS-CoV-2 特异性记忆 B 细胞反应相当。我们的结果表明，灭活 SARS-CoV-2 疫苗（BBIBP-CorV 和 CoronaVac）是安全的，但其免疫原性在 AILD 患者中受到损害。此外，免疫抑制剂与 SARS-CoV-2 疫苗的抗体反应不佳显着相关。这些结果可以帮助医生和政策制定者做出决定，筛选对 SARS-CoV-2 疫苗抗体反应不佳的高风险人群，并为 AILD 患者提供额外疫苗接种。
The antibody and B cell responses after inactivated SARS-CoV-2 vaccination have not been well documented in patients with autoimmune liver disease (AILD). Therefore, we conducted a prospective observational study that included AILD patients and healthy participants as controls between July 1, 2021, and September 30, 2021, at the Second Affiliated Hospital of Chongqing Medical University. All adverse events (AEs) after the COVID-19 vaccination were recorded and graded. Immunoglobulin (Ig)-G antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (anti-RBD-IgG) and neutralizicadng antibodies (NAbs) were tested following full-course vaccination (BBIBP-CorV or CoronaVac). In addition, SARS-CoV-2-specific B cells were detected by flow cytometry. In total, 76 AILD patients and 136 healthy controls (HCs) were included. All AEs were mild and self-limiting, and the incidences were similar between the AILD and HCs. The seropositivity rates of anti-RBD-IgG and NAbs in AILD were 97.4% (100% in HCs, p = 0.13) and 63.2% (84.6% in HCs, p < 0.001), respectively. The titers of anti-RBD-IgG and NAbs were significantly lower in AILD patients than those in HCs. After adjusting for confounders, immunosuppressive therapy was an independent risk factor for low-level anti-RBD-IgG (adjusted odds ratio [aOR]: 4.7; 95% confidence interval [CI], 1.5-15.2; p = 0.01) and a reduced probability of NAbs seropositivity (aOR, 3.0; 95% CI, 1.0-8.9; p = 0.04) in AILD patients. However, regardless of immunosuppressants, the SARS-CoV-2-specific memory B cells responses were comparable between the AILD and HC groups. Our results suggest that inactivated SARS-CoV-2 vaccines (BBIBP-CorV and CoronaVac) are safe, but their immunogenicity is compromised in patients with AILD. Moreover, immunosuppressants are significantly associated with poor antibody responses to the SARS-CoV-2 vaccines. These results could inform physicians and policymakers about decisions on screening the populations at higher risk of poor antibody responses to SARS-CoV-2 vaccines and providing additional vaccinations in patients with AILD.
登录
查看更多内容
影响因子：
12.8
作者：
Tzioufas AG;Bakasis AD;Goules AV;Bitzogli K;Cinoku II;Chatzis LG;Argyropoulou OD;Venetsanopoulou AI;Mavrommati M;Stergiou IE;Pezoulas V;Voulgari PV;Katsimpari C;Katechis S;Gazi S;Katsifis G;Sfontouris CI;Georgountzos AI;Liossis SN;Papagoras C;Fotiadis DI;Skopouli FN;Vlachoyiannopoulos PG;Moutsopoulos HM
通讯作者：
Moutsopoulos HM
影响因子：
12.8
作者：
Ferri C;Ursini F;Gragnani L;Raimondo V;Giuggioli D;Foti R;Caminiti M;Olivo D;Cuomo G;Visentini M;Cacciapaglia F;Pellegrini R;Pigatto E;Urraro T;Naclerio C;Tavoni A;Puccetti L;Varcasia G;Cavazzana I;L'Andolina M;Ruscitti P;Vadacca M;Gigliotti P;La Gualana F;Cozzi F;Spinella A;Visalli E;Dal Bosco Y;Amato G;Masini F;Pagano Mariano G;Brittelli R;Aiello V;Caminiti R;Scorpiniti D;Rechichi G;Ferrari T;Monti M;Elia G;Franceschini F;Meliconi R;Casato M;Iannone F;Giacomelli R;Fallahi P;Santini SA;Zignego AL;Antonelli A
通讯作者：
Antonelli A
影响因子：
25.7
作者：
Lohse, Ansgar W.;Chazouilleres, Olivier;Lenzi, Marco
通讯作者：
Lenzi, Marco
影响因子：
13.5
作者：
Mack, Cara L.;Adams, David;Czaja, Albert J.
通讯作者：
Czaja, Albert J.
影响因子：
15.9
作者：
Ogega, Clinton O.;Skinner, Nicole E.;Bailey, Justin R.
通讯作者：
Bailey, Justin R.